Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices for individuals with spinal cord injury; ReStore Exo-Suit, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals' post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as ReWalk Robotics Ltd. and changed its name to Lifeward Ltd. in September 2024. Lifeward Ltd. was incorporated in 2001 and is based in Yokneam Illit, Israel.…
Lifeward: Q3 Earnings Snapshot
Lifeward (NASDAQ: LFWD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 81 employees.
The shares were at 2.803 USD on 20 November 2026, down 55.8% over 52 weeks. Its 52-week range is 2.730 USD to 9.610 USD: the price is 70.8% below the high and 2.7% above the low.
Its market capitalisation is 7.96M USD.
Lifeward reports return on equity of -236.8%, an operating margin of -124.4% and revenue down 12.4% year over year.
Its debt exceeds its cash by 5.06M USD, a debt-to-equity ratio of 0.52. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 8.500 USD is 203.2% above the current price. The next earnings report is expected on 17 March 2027.